Debdulal Chakraborty

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Cataract Surgery

Age Related Macular Degeneration

Top Venues

Clinical ophthalmology (Auckland, N.Z.)

Ophthalmology and therapy

Eye (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Debdulal Chakraborty, Subhendu Boral, Tushar Kanti Sinha, Arnab Das, Angshuman Mukherjee, Saptorshi Majumdar, Ranabir Bhattacharya, Ritobroto Maitra
Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study. Clinical ophthalmology (Auckland, N.Z.) 18 (2024)
Debdulal Chakraborty, Subhendu Boral, Tushar Kanti Sinha, Arnab Das, Angshuman Mukherjee, Saptorshi Majumdar, Ranabir Bhattacharya, Ritobroto Maitra
Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study. Clinical ophthalmology (Auckland, N.Z.) 18 (2024)
Debdulal Chakraborty, Soumen Mondal, Subhendu Boral, Arnab Das, Tushar Kanti Sinha, Saptorshi Majumdar, Ranabir Bhattacharya, Ritobroto Maitra
Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence. Clinical ophthalmology (Auckland, N.Z.) 17 (2023)
Debdulal Chakraborty, Milan Thakkar, Ramesh Venkatesh, Sangeeta Roy, Maulik Bhavsar, Helene Karcher
Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study. Clinical ophthalmology (Auckland, N.Z.) 17 (2023)
Debdulal Chakraborty, Aniruddha Maiti, Jay Umed Sheth, Soumen Mondal, Subhendu Boral, Krishnendu Nandi, Tushar Kanti Sinha, Arnab Das
Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study - Fifty-Two-Week Outcomes. Clinical ophthalmology (Auckland, N.Z.) 16 (2022)
Debdulal Chakraborty, Sabyasachi Sengupta, Soumen Mondal, Subhendu Boral, Arnab Das, Tushar Kanti Sinha, Ranabir Bhattacharya, Ritobroto Maitra
Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study. Ophthalmology and therapy 11 (2) (2022)
Debdulal Chakraborty, Aniruddha Maiti, Jay Umed Sheth, Soumen Mondal, Subhendu Boral, Krishnendu Nandi, Tushar Kanti Sinha, Arnab Das
Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study - Fifty-Two-Week Outcomes. Clinical ophthalmology (Auckland, N.Z.) 16 (2022)
Debdulal Chakraborty, Michael W Stewart, Jay U Sheth, Tushar K Sinha, Subhendu Boral, Arnab Das, Soumen Mondal, Angshuman Mukherjee
Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases. Ophthalmology and therapy 10 (2) (2021)
Debdulal Chakraborty, Aniruddha Maiti, Jay Umed Sheth, Subhendu Boral, Soumen Mondal, Krishnendu Nandi, Tushar Sinha, Arnab Das
Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study. Clinical ophthalmology (Auckland, N.Z.) 15 (2021)
Debdulal Chakraborty, Soumen Mondal, Nikulaa Parachuri, Nilesh Kumar, Ashish Sharma
Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedema. Eye (London, England) (2021)